Role Of microRNAs In The Development Of Aggressive Forms Of Prostate Cancer
- Authors: Chernogubova E.A1, Mashkarina A.N1
-
Affiliations:
- Federal Research Centre the Southern Scientific Centre of the Russian Academy of Sciences
- Issue: Vol 19, No 4 (2023)
- Pages: 109-116
- Section: Articles
- URL: https://journals.eco-vector.com/2500-0640/article/view/628065
- DOI: https://doi.org/10.7868/S25000640230411
- ID: 628065
Cite item
Abstract
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer deaths among men. Complex genetic and epigenetic mechanisms are involved in the development and progression of prostate cancer. In recent years, evidence has been accumulating that aberrant microRNA expression contributes to the development of hormone resistance and radioresistance in prostate cancer. MicroRNAs are short non-coding RNAs involved in the process of post-transcriptional regulation of genes. Numerous studies have demonstrated that microRNAs are targeted on and regulate critical genes involved in prostate cancer aggressiveness. However, the molecular mechanisms underlying the involvement of microRNAs in treatment-resistant prostate cancer remain unclear. The purpose of the review is to analyze the role of microRNAs in the molecular mechanisms of the development of clinically aggressive forms of prostate cancer. A wide range of target genes and a significant change in microRNA expression profiles during the transition of malignant cells to a radioresistant and hormone resistant state makes microRNAs promising candidates for searching for prognostic markers for the development of aggressive forms of prostate cancer and determining targets for targeted therapy. Analysis of key microRNAs involved in the development of clinically aggressive forms of prostate cancer has shown that the molecular mechanisms by which microRNAs mediate the development of hormone resistance and radioresistance in prostate cancer include apoptosis, cell growth and proliferation, cancer stem cells, autophagy, regulation of epithelial-mesenchymal transition, as well as cell migration and invasion.
Keywords
About the authors
E. A Chernogubova
Federal Research Centre the Southern Scientific Centre of the Russian Academy of Sciences
Email: eachernogubova@mail.ru
Rostov-on-Don, Russian Federation
A. N Mashkarina
Federal Research Centre the Southern Scientific Centre of the Russian Academy of Sciences
Email: aina_mashkarina@mail.ru
Rostov-on-Don, Russian Federation
References
- Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). 2022. М., Московский научно-исследовательский онкологический институт им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России: 252 с.
- Siegel R.L., Miller K.D., Fuchs H.E., Jemal A. 2022. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 72(1): 7‒33. doi: 10.3322/caac.21708
- Soares S., Guerreiro S.G., Cruz-Martins N., Faria I., Baylina P., Sales M.G., Correa-Duarte M.A., Fernandes R. 2021. The influence of miRNAs on radiotherapy treatment in prostate cancer ‒ A systematic review. Frontiers in Oncology. 11: 704664. doi: 10.3389/fonc.2021.704664
- Morote J., Aguilar A., Planas J., Trilla E. 2022. Definition of castrate resistant prostate cancer: new insights. Biomedicines. 10(3): 689. doi: 10.3390/biomedicines10030689
- O’Brien J., Hayder H., Zayed Y., Peng C. 2018. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Frontiers in Endocrinology. 9: 402. doi: 10.3389/fendo.2018.00402
- Махоткин М.А., Чеботарев Д.А., Тютякина М.Г., Машкарина А.Н., Тарасов В.А., Коган М.И., Черногубова Е.А. 2021. Роль микроРНК в развитии радиорезистентности клеток рака предстательной железы (экспериментальное исследование). Онкоурология. 17(4): 85‒93. doi: 10.17650/1726-9776-2021-17-4-85-93
- Doghish A.S., Ismail A., El-Mahdy H.A., Elkady M.A., Elrebehy M.A., Sallam A.-A.M. 2022. A review of the biological role of miRNAs in prostate cancer suppression and progression. International Journal of Biological Macromolecules. 197: 141‒156. doi: 10.1016/j.ijbiomac.2021.12.141
- Sidorova E.A., Zhernov Yu.V., Antsupova M.A., Khadzhieva K.R., Izmailova A.A., Kraskevich D.A., Belova E.V., Simanovsky A.A., Shcherbakov D.V., Zabroda N.N., Mitrokhin O.V. 2023. The role of different types of microRNA in the pathogenesis of breast and prostate cancer. International Journal of Molecular Sciences. 24(3): 1980. doi: 10.3390/ijms24031980
- Ali Syeda Z., Langden S.S.S., Munkhzul C., Lee M., Song S.J. 2020. Regulatory mechanism of microRNA expression in cancer. International Journal of Molecular Sciences. 21(5): 1723. doi: 10.3390/ijms21051723
- Gujrati H., Ha S., Wang B.D. 2023. Deregulated microRNAs involved in prostate cancer aggressiveness and treatment resistance mechanisms. Cancers. 15(12): 3140. doi: 10.3390/cancers15123140
- Huang K., Sun X., Wu H., Zhao J., Jian Y., Xu Z., Wang S., Yang D. 2021. The regulating effect of autophagy-related miRNAs in kidney, bladder, and prostate cancer. Journal of Oncology. 2021: 5510318. doi: 10.1155/2021/5510318
- Ding L., Wang R., Shen D., Cheng S., Wang H., Lu Z., Zheng Q., Wang L., Xia L., Li G. 2021. Role of noncoding RNA in drug resistance of prostate cancer. Cell Death and Disease. 12(6): 590. doi: 10.1038/s41419-021-03854-x
- Ebrahimi S., Hashemy S.I., Sahebkar A., Aghaee Bakhtiari S.H. 2021. MicroRNA regulation of androgen receptor in castration-resistant prostate cancer: premises, promises, and potentials. Current Molecular Pharmacology. 14: 559–569. doi: 10.2174/1874467213666201223121850
- Labbé M., Hoey C., Ray J., Potiron V., Supiot S., Liu S.K., Fradin D. 2020. MicroRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. Molecular Cancer. 19: 63. doi: 10.1186/s12943-020-01186-6
- Малек А.В., Берштейн Л.М. 2015. МикроРНК: половые гормоны, гормональный канцерогенез, гормоночувствительность опухолевой ткани. Успехи молекулярной онкологии. 2(1): 004–012. doi: 10.17650/2313-805X.2015.2.1.004–012
- Имянитов Е.Н. 2008. Эпидемиология и биология рака простаты. Практическая онкология. 9(2): 57‒64.
- Fletcher C.E., Sulpice E., Combe S., Shibakawa A., Leach D.A., Hamilton M.P., Chrysostomou S.L., Sharp A., Welti J., Yuan W., Dart D.A., Knight E., Ning J., Francis J.C., Kounatidou E.E., Gaughan L., Swain A., Lupold S.E., de Bono J.S., McGuire S.E., Gidrol X., Bevan C.L. 2019. Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. Oncogene. 38(28): 5700–5724. doi: 10.1038/s41388-019-0823-5
- Eringyte I., Zamarbide Losada J.N., Powell S.M., Bevan C.L., Fletcher C.E. 2020. Coordinated AR and microRNA regulation in prostate cancer. Asian Journal of Urology. 7(3): 233–250. doi: 10.1016/j.ajur.2020.06.003
- Sikand K., Slaibi J.E., Singh R., Slane S.D., Shukla G.C. 2011. mir 488* inhibits androgen receptor expression in prostate carcinoma cells. International Journal of Cancer. 129(4): 810–819. doi: 10.1002/ijc.25753
- Bielska A., Skwarska A., Kretowski A., Niemira M. 2022. The role of androgen receptor and microRNA interactions in androgen-dependent diseases. International Journal of Molecular Sciences. 23(3): 1553. doi: 10.3390/ijms23031553
- Kashat M., Azzouz L., Sarkar S.H., Kong D., Li Y., Sarkar F.H. 2012. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. American Journal of Translational Research. 4(4): 432–442.
- Aakula A., Leivonen S.K., Hintsanen P., Aittokallio T., Ceder Y., Borresen-Dale A.L., Perala M., Ostling P., Kallioniemi O. 2015. MicroRNA-135b regulates ERalpha, AR and HIF1AN and affects breast and prostate cancer cell growth. Molecular Oncology. 9(7): 1287–1300. doi: 10.1016/j.molonc.2015.03.001
- Kumar B., Khaleghzadegan S., Mears B., Hatano K., Kudrolli T.A., Chowdhury W.H., Yeater D.B., Ewing C.M., Luo J., Isaacs W.B., Marchionni L., Lupold S.E. 2016. Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening. Oncotarget. 7: 72593–72607. doi: 10.18632/oncotarget.12241
- Borrego-Diaz E., Powers B.C., Azizov V., Lovell S., Reyes R., Chapman B., Tawfik O., McGregor D., Diaz F.J., Wang X., Veldhuizen P.V. 2014. A potential regulatory loop between Lin28B: miR212 in androgen-independent prostate cancer. International Journal of Oncology. 45(6): 2421–2429. doi: 10.3892/ijo.2014.2647
- Bernard D., Pourtier-Manzanedo A., Gil J., Beach D.H. 2003. Myc confers androgen-independent prostate cancer cell growth. Journal of Clinical Investigation. 112(11): 1724–1731. doi: 10.1172/JCI19035
- Tummala R., Nadiminty N., Lou W., Zhu Y., Gandour-Edwards R., Chen H.W., Evans C.P., Gao A.C. 2013. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. American Journal of Pathology. 183(1): 288–295. doi: 10.1016/j.ajpath.2013.03.011
- Ramalinga M., Roy A., Srivastava A., Bhattarai A., Harish V., Suy S., Collins S., Kumar D. 2015. MicroRNA-212 negatively regulates starvation induced autophagy in prostate cancer cells by inhibiting SIRT1 and is a modulator of angiogenesis and cellular senescence. Oncotarget. 6(33): 34446–34457. doi: 10.18632/oncotarget.5920
- Qu F., Cui X., Hong Y., Wang J., Li Y., Chen L., Liu Y., Gao Y., Xu D., Wang Q. 2013. MicroRNA-185 suppresses proliferation, invasion, migration, and tumorigenicity of human prostate cancer cells through targeting androgen receptor. Molecular and Cellular Biochemistry. 377(1‒2): 121–130. doi: 10.1007/s11010-013-1576-z
- Jiang C.Y., Ruan Y., Wang X.H., Zhao W., Jiang Q., Jing Y.F., Han B.M., Xia S.J., Zhao F.J. 2016. MiR-185 attenuates androgen receptor function in prostate cancer indirectly by targeting bromodomain containing 8 isoform 2, an androgen receptor co-activator. Molecular and Cellular Endocrinology. 427: 13–20. doi: 10.1016/j.mce.2016.02.023
- Li X., Chen Y.T., Josson S., Mukhopadhyay N.K., Kim J., Freeman M.R., Huang W.C. 2013. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS ONE. 8(8): e70987. doi: 10.1371/journal.pone.0070987
- Ma S., Chan Y.P., Kwan P.S., Lee T.K., Yan M., Tang K.H., Ling M.T., Vielkind J.R., Guan X.-Y., Chan K.W. 2011. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Research. 71(2): 583–592.doi: 10.1158/0008-5472.CAN-10-2587
- Konduri S.D., Tasiou A., Chandrasekar N., Rao J.S. 2001. Overexpression of tissue factor pathway inhibitor-2 (TFPI-2), decreases the invasiveness of prostate cancer cells in vitro. International Journal of Oncology. 18(1): 127–131.
- Jiao L., Deng Z., Xu C., Yu Y., Li Y., Yang C., Chen J., Liu Z., Huang G., Li L.-C., Sun Y. 2014. miR-663 induces castrationresistant prostate cancer transformation and predicts clinical recurrence. Journal of Cellular Physiology. 229(7): 834–844. doi: 10.1002/jcp.24510
- Sementchenko V.I., Schweinfest C.W., Papas T.S., Watson D.K. 1998. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene. 17(22): 2883–2888. doi: 10.1038/sj.onc.1202220
- Yang X., Yang Y., Gan R., Zhao L., Li W., Zhou H., Wang X., Lu J., Meng Q.H. 2014. Down-regulation of mir-221 and mir-222 restrain prostate cancer cell proliferation and migration that is partly mediated by activation of SIRT1. PLoS ONE. 9(6): 98833. doi: 10.1371/journal.pone.0098833
- Wang L., Liu C., Li C., Xue J., Zhao S., Zhan P., Lin Y., Zhang P., Jiang A., Chen W. 2015. Effects of microRNA-221/222 on cell proliferation and apoptosis in prostate cancer cells. Gene. 572(2): 252–258. doi: 10.1016/j.gene.2015.07.017
- Kobayashi T., Inoue T., Shimizu Y., Terada N., Maeno A., Kajita Y., Yamasaki T., Kamba T., Toda Y., Mikami Y., Yamada T., Kamoto T., Ogawa O., Nakamura E. 2010. Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo. Molecular Endocrinology. 24(4): 722–734. doi: 10.1210/me.2009-0326
- Rönnau C.G.H., Fussek S., Smit F.P., Aalders T.W., van Hooij O., Pinto P.M.C., Burchardt M., Schalken J.A., Verhaegh G.W. 2021. Upregulation of miR-3195, miR-3687 and miR-4417 is associated with castration-resistant prostate cancer. World Journal of Urology. 39(10): 3789–3797. doi: 10.1007/s00345-021-03723-4
- Naidoo M., Levine F., Gillot T., Orunmuyi A.T., Olapade-Olaopa E.O., Ali T., Krampis K., Pan C., Dorsaint P., Sboner A., Ogunwobi O.O. 2021. MicroRNA-1205 regulation of FRYL in prostate cancer. Frontiers in Cell and Developmental Biology. 9: 647485. doi: 10.3389/fcell.2021.647485
- Zhao L., Lu X., Cao Y. 2013. MicroRNA and signal transduction pathways in tumor radiation response. Cellular Signalling. 25(7): 1625–1634. doi: 10.1016/j.cellsig.2013.04.004
- Wang F., Mao A., Tang J., Zhang Q., Yan J., Wang Y., Di C., Gan L., Sun C., Zhang H. 2019. MicroRNA-16-5p enhances radiosensitivity through modulating cyclin D1/E1-pRb-E2F1 pathway in prostate cancer cells. Journal of Cellular Physiology. 234(8): 13182–13190. doi: 10.1002/jcp.27989
- Yadav S., Kowolik C.M., Lin M., Zuro D., Hui S.K., Riggs A.D., Horne D.A. 2019. SMC1A is associated with radioresistance in prostate cancer and acts by regulating epithelial-mesenchymal transition and cancer stem-like properties. Molecular Carcinogenesis. 58(1): 113–125. doi: 10.1002/mc.22913
- El Bezawy R., Tinelli S., Tortoreto M., Doldi V., Zuco V., Folini M., Stucchi C., Rancati T., Valdagni R., Gandellini P., Zaffaroni N. 2019. miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition. Journal of Experimental and Clinical Cancer Research. 38(1): 51. doi: 10.1186/s13046-019-1060-z
- Josson S., Sung S.-Y., Lao K., Chung L.W.K., Johnstone P.A.S. 2008. Radiation modulation of microRNA in prostate cancer cell lines. Prostate. 68(15): 1599‒1606. doi: 10.1002/pros.20827
- Huang X., Taeb S., Jahangiri S., Emmenegger U., Tran E., Bruce J., Mesci A., Korpela E., Vesprini D., Wong C.S., Bristow R.G., Liu F.-F., Liu S.K. 2013. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Research. 73(23): 6972‒6986. doi: 10.1158/0008-5472.CAN-13-1657
- Hudson R.S., Yi M., Esposito D., Glynn S.A., Starks A.M., Yang Y., Schetter A.J., Watkins S.K., Hurwitz A.A., Dorsey T.H., Stephens R.M., Croce C.M., Ambs S. 2013. MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene. 32(35): 4139‒4147. doi: 10.1038/onc.2012.424
- Li B., Shi X.-B., Nori D., Chao C.K.S., Chen A.M., Valicenti R., de Vere White R. 2011. Down-regulation of microRNA 106b is involved in p21-mediated cell cycle arrest in response to radiation in prostate cancer cells. Prostate. 71(6): 567‒574. doi: 10.1002/pros.21272
- Chebotarev D.A., Makhotkin M.A., Naboka A.V., Tyutyakina M.G., Cherkasova E.N., Tarasov V.A. 2019. Involvement of microRNAs in regulation of radioresistance of HeLa and DU145 cells. Russian Journal of Genetics. 55(9): 1072‒1081. doi: 10.1134/S1022795419090047
- Zhou J., Du T., Li B., Rong Y., Verkhratsky A., Peng L. 2015. Crosstalk between MAPK/ERK and PI3K/AKT signal pathways during brain ischemia/reperfusion. ASN Neuro. 7(5): 1759091415602463. doi: 10.1177/1759091415602463
- Xu J., Zhang W., Lv Q., Zhu D. 2015. Overexpression of miR-21 promotes the proliferation and migration of cervical cancer cells via the inhibition of PTEN. Oncology Reports. 33(6): 3108–3116. doi: 10.3892/or.2015.3931
- Macedo-Silva C., Benedetti R., Ciardiello F., Cappabianca S., Jerónimo C., Altucci L. 2021. Epigenetic mechanisms underlying prostate cancer radioresistance. Clinical Epigenetics. 13(1): 125. doi: 10.1186/s13148-021-01111-8
- Richardsen E., Andersen S., Al-Saad S., Rakaee M., Nordby Y., Pedersen M.I., Ness N., Ingebriktsen L.M., Fassina A., Taskén K.A., Mills I.G., Donnem T., Bremnes R.M., Busund L.T. 2019. Low expression of miR-424-3p is highly correlated with clinical failure in prostate cancer. Scientific Reports. 9(1): 10662. doi: 10.1038/s41598-019-47234-0
- Kim M.Y., Shin H., Moon H.W., Park Y.H., Park J., Lee J.Y. 2021. Urinary exosomal microRNA profiling in intermediate-risk prostate cancer. Scientific Reports. 11(1): 7355. doi: 10.1038/s41598-021-86785-z
- Jalava S.E., Urbanucci A., Latonen L., Waltering K.K., Sahu B., Janne O.A., Seppala J., Lahdesmaki H., Tammela T.L., Visakorpi T. 2012. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 31(41): 4460–4471. doi: 10.1038/onc.2011.624
- Coppola V., Musumeci M., Patrizii M., Cannistraci A., Addario A., Maugeri-Sacca M., Biffoni M., Francescangeli F., Cordenonsi M., Piccolo S., Memeo L., Pagliuca A., Muto G., Zeuner A., De Maria R., Bonci D. 2013. BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial-mesenchymal transition. Oncogene. 32(14): 1843–1853. doi: 10.1038/onc.2012.194
- Liao H., Xiao Y., Hu Y., Xiao Y., Yin Z., Liu L. 2015. microRNA-32 induces radioresistance by targeting DAB2IP and regulating autophagy in prostate cancer cells. Oncology Letters. 10(4): 2055–2062. doi: 10.3892/ol.2015.3551
- Verdoodt B., Neid M., Vogt M., Kuhn V., Liffers S.T., Palisaar R.J., Noldus J., Tannapfel A., Mirmohammadsadegh A. 2013. MicroRNA-205, a novel regulator of the anti-apoptotic protein Bcl2, is downregulated in prostate cancer. International Journal of Oncology. 43(1): 307‒314. doi: 10.3892/ijo.2013.1915
- Hulf T., Sibbritt T., Wiklund E.D., Patterson K., Song J.Z., Stirzaker C., Qu W., Nair S., Horvath L.G., Armstrong N.J., Kench J.G., Sutherland R.L., Clark S.J. 2013. Epigenetic-induced repression of microRNA-205 is associated with MED1 activation and a poorer prognosis in localized prostate cancer. Oncogene. 32(23): 2891‒2899. doi: 10.1038/onc.2012.300
- Tucci P., Agostini M., Grespi F., Markert E.K., Terrinoni A., Vousden K.H., Muller P.A., Dotsch V., Kehrloesser S., Sayan B.S., Giaccone G., Lowe S.W., Takahashi N., Vandenabeele P., Knight R.A., Levine A.J., Melino G. 2012. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasisin prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 109(38): 15312‒15317. doi: 10.1073/pnas.1110977109
- Wang W., Liu J., Wu Q. 2016. MiR-205 suppresses autophagy and enhances radiosensitivity of prostate cancer cells by targeting TP53INP1. European Review for Medical and Pharmacological Sciences. 20(1): 92‒100.